NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

癌症腫瘤分析的全球市場:2020年∼2027年

Global Cancer Tumor Profiling Market - 2020-2027

出版商 DataM Intelligence 商品編碼 1004516
出版日期 內容資訊 英文 180 Pages
商品交期: 約2個工作天內
價格
癌症腫瘤分析的全球市場:2020年∼2027年 Global Cancer Tumor Profiling Market - 2020-2027
出版日期: 2021年05月10日內容資訊: 英文 180 Pages
簡介

全球癌症腫瘤分析市場成長的主要因素有癌症數量的增加,資助旨在改善疾病診斷和治療整體過程的研發活動,以及最近的腫瘤分析。技術進步,提高對床旁診斷的接受度,以及對個性化醫療的需求激增。

本報告提供全球癌症腫瘤分析市場相關調查分析,提供產業分析,各市場區隔的市場分析,競爭情形,主要企業等相關的系統性資訊。

目錄

第1章 全球癌症腫瘤分析市場調查手法與調查範圍

第2章 全球癌症腫瘤分析市場:市場定義與市場概要

第3章 全球癌症腫瘤分析市場:摘要整理

第4章 全球癌症腫瘤分析市場:市場動態

  • 影響市場的要素
    • 促進因素
    • 阻礙因素
    • 市場機會
    • 影響分析

第5章 全球癌症腫瘤分析市場:產業分析

  • 波特的五力分析
  • 供應鏈分析
  • 價格分析
  • 法規分析
  • 償付分析
  • 未滿足需求

第6章 全球癌症腫瘤分析市場:COVID-19分析

  • COVID-19對市場的影響分析
  • 在COVID-19中的價格趨勢
  • 需求與供給的頻譜
  • 疫情期間與市場相關的政府舉措
  • 製造商策略性舉措
  • 結論

第7章 全球癌症腫瘤分析市場:癌症的各類型

  • 簡介
  • 癌症的不同種類的市場規模分析·與前一年同期比較成長率分析
  • 癌症的不同種類的市場魅力指數
    • 前列腺癌症
    • 乳癌
    • 大腸癌症
    • 黑色素瘤
    • 其他

第8章 全球癌症腫瘤分析市場:各技術類型

  • 簡介
  • 各技術類型的市場規模分析·與前一年同期比較成長率分析
  • 各技術類型的市場魅力指數
    • 免疫測量
    • 次世代定序
    • 聚合酵素鏈鎖反應 (PCR)
    • 原位 雜合反應
    • 微陣列
    • 其他

第9章 全球癌症腫瘤分析市場:生物標記各類型

  • 簡介
  • 生物標記各類型的市場規模分析·與前一年同期比較成長率分析
  • 生物標記各類型的市場魅力指數
    • 基因學生物標記
    • 蛋白質生物標記
    • 其他

第10章 全球癌症腫瘤分析市場:各用途

  • 簡介
  • 各用途的市場規模分析·與前一年同期比較成長率分析
  • 各用途的市場魅力指數
    • 研究用途
    • 臨床應用
    • 診斷
    • 個人化醫療
    • 其他

第11章 全球癌症腫瘤分析市場:各地區

  • 簡介
  • 各地區的市場規模分析·與前一年同期比較成長率分析
  • 各地區的市場魅力指數
  • 北美
  • 歐洲
  • 南美
  • 亞太地區
  • 中東·非洲

第12章 全球癌症腫瘤分析市場:企業簡介

  • Illumina Inc
  • QIAGEN N.V
  • NeoGenomics Laboratories
  • Genomic Health Inc
  • Caris Life Sciences
  • Helomics Corporation
  • NanoString Technologies, Inc
  • Sysmex Corporation
  • Ribomed Biotechnologies, Inc
  • Roche Diagnostics等

第13章 全球癌症腫瘤分析市場:重要考察

第14章 全球癌症腫瘤分析市場:DataM

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Market Overview

The Global Cancer Tumor Profiling Market size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2027, growing at a CAGR of XX % during the forecast period (2020-2027).

Cancer is generally the proliferation of uncontrolled cell growth, which could be fatal. Environmental reasons mainly cause altering a gene encoding, which triggers cell regulation, and the cell mutation leads to uncontrolled cell growth, which affects the neighboring cells and organs. Cancer tumor profiling provides information about the genes causing cancer, which would offer valuable insights related to the mechanism of cancer. The potential of cancer profiling is limited to common cancers, such as lymphoma and breast cancer, and is helpful in molecular profiling of lung cancer, prostate cancer, and acute leukemia. Cancer profiling has played a vital role in diagnosis at the molecular level, as a better understanding of the cancer tumors helps physicians make appropriate therapeutic decisions and avoid "over-treatment" of the cancer patients.

Market Dynamics

The global Cancer Tumor Profiling market growth is driven by the growing incidence of Cancer cases, Raising funds in research and development activities aimed at improving the overall course of diagnosis and treatment of the disease and growing technological advancements recently observed in tumor profiling, increasing acceptance of point of care diagnostics and the rise in demand for personalized medicines.

Growing incidence of cancer cases globally, is expected to drive the global Cancer Tumor Profiling market growth.

As per the World Health Organization (WHO), Cancer is the second-most leading cause of death worldwide, accounting for over 18.1 million cases were diagnosed in 2018. In 2020, around 19 Mn new cancer cases were diagnosed across the world as per the WHO. Likewise, the American Cancer Society reported that 89,500 cases were diagnosed in the U.S. in 2020. Additionally, according to International Agency for Research on Cancer (IARC) estimates, by 2040, global cancer cases are expected to grow to 27.5 million new cancer cases worldwide. This number has led to an increase in the adoption of various tumor profiling methods.

Technical issues in sample collection and storage conditions are likely hindering the global cancer tumor profiling market

Sample collection is one of the major issues faced by service providers, followed by access to these samples. Stringent quality control of these samples is required, and they need to be stored under the proper conditions to avoid any loss.

COVID-19 Impact Analysis

The COVID-19 pandemic has negatively impacted healthcare systems globally and majorly on the Personalized Cancer Vaccines. As per the article published in Cancer Connect 2020, doctors from Dana Farber Cancer Institute determined that during the COVID-19 pandemic, there was a 46% decrease in the diagnoses of the six most common cancer types - breast, colorectal, lung, pancreatic, gastric, and esophageal cancers. According to the Centers for Disease Control and Prevention (CDC) and many medical professional organizations recommended that cancer screening and other health prevention services, along with elective surgeries, be postponed unless the risks outweighed the benefits and secure the hospital infrastructure for the treatment of COVID-19 patients. Thus, the COVID-19 pandemic has impacted the On-going clinical trials too. However, the situation is expected to improve gradually.

Segment Analysis

Based on the Cancer Type, the global Cancer Tumor Profiling market is segmented into Breast Cancer, Lung cancer, Prostate cancer, Colorectal cancer, Melanoma cancer and Others

The Lung cancer segment is expected to grow at the fastest CAGR during the forecast period (2020-2027).

The increasing prevalence of lung cancer worldwide and the rising need for early diagnosis support this segment's major growth. Lung cancer (both small and non-small cells) is the second most common cancer in both men and women. Most lung cancer statistics include small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC). In general, about 13% of all lung cancers are SCLC, and 84% are NSCLC. As per the American Cancer Society's estimates for lung cancer in the United States for 2021 are about 235,760 new cases of lung cancer (119,100 in men and 116,660 in women). These factors increasing the global Cancer Tumor Profiling market growth.

Based on the Technology Type, the global Cancer Tumor Profiling market is segmented into Immunoassay, Next-generation Sequencing, Polymerase chain reaction, In-Situ Hybridization, Microarray

The immunoassays segment accounted for the largest market share. The immunoassays are used as a gold standard to conduct tumor profiling on a large scale because they help measure the presence and concentration of analytes in a sample, and these tests are used for tumor diagnosis, prognosis, and also treatment decisions. Moreover, the information gained by conducting these tests in clinical settings helps to shorten hospital stay period and decrease the severity of illnesses by identifying and assessing the progression of the disease, leading to improved therapeutic choices. The high sensitivity and cost-effectiveness of these techniques and technological improvements in these immunoassays tests are some factors expected to drive the growth of this market during the forecast period. For instance, On June 1, 2021, Nantes University Hospital, in collaboration with Roche Diagnostics developing a study that aims to explore the sensitivity of an innovative marker, HE4, in the diagnosis approach of endometrial cancer in the case of postmenopausal bleedings.

Based on the Biomarker Type, the global Cancer Tumor Profiling market is segmented into Genomic biomarker and Protein biomarker.

The large share of the genomics segment can be attributed to the high adoption of these biomarkers during cancer diagnosis and prognosis and the biomarker discovery process. Genomics plays a vital role in the detection of these genetic variations in cases of reoccurrence. These genomic platforms have proven advantageous as they lead to cost savings, improve screening time, and help identify a larger size of the evaluated genome. These factors are likely to encourage the usage of genomics sciences for tumor profiling in the coming years. For instance, Lucence Health Inc, in 2021, started developing Liquid Biopsy technology for the detection of Actionable Genomic Biomarkers in Patients with Advanced Non-small Cell Lung Cancer (NSCLC).

Based on the application, the global cancer tumor profiling market is segmented into Research, Diagnostics, Personalized medicines and clinical applications.

The research applications segment expected the largest share of cancer/tumor profiling market in the forecast period. The large share of this segment is attributed to the increasing focus on biomarker discovery for drug development along with the rapidly growing field of personalized medicine. Additionally, the growing funding for cancer research is propelling the growth of the market.

Geographical Analysis

North America region holds the largest market share global Cancer Tumor Profiling market

North America holds the largest market in the global cancer stem cells market due to the high incidence of cancer, according to the International Agency for Research on Cancer (IARC), which claims 13 million new cancer cases worldwide. The World Cancer Report provides that the incidence rate of new cancer cases is increased by 50% to 15 million in 2020. The existence of a highly developed healthcare system, the high degree of acceptance by medical practitioners of novel chemotherapy and immunotherapy methods, the total availability of advanced technological tools, FDA approval of new drugs and also the presence of a vast number of organizations engaged in R&D activities related to cancer vaccines.

The Asia Pacific is expected to be the fastest-growing market over the forecast period owing to increasing prevalence rate, increasing focus on preventive care, and government initiatives promoting technological innovations. For instance, Molecular Profiling in Small Cell Lung Cancer by Zhujiang Hospital is estimated to complete by September 2021.

Competitive Landscape

The Global Cancer Tumor Profiling Market is quite competitive with some key competitors like Illumina, Inc, QIAGEN N.V, NeoGenomics Laboratories, Genomic Health Inc, Caris Life Sciences, Helomics Corporation, NanoString Technologies, Inc, Sysmex Corporation, Ribomed Biotechnologies, Inc, Roche Diagnostics. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, contributing to the market's growth globally. For instance, in 2018, Illumina Inc acquired Edico Genome, a leading provider of data analysis acceleration solutions for next generation sequencing (NGS), to accelerate genomic data analysis.

Illumina Inc

Overview: Illumina is an American company incorporated in 1998. Its headquarters are located in San Diego, California. It is a molecular diagnostics company engaged in the development, manufacturing, and marketing of integrated systems for the analysis of genetic variations and biological functions. The company offers a wide range of integrated sequencing and microarray systems, consumables, and analysis tools to accelerate and simplify genetic analysis.

Product Portfolio: The company operates under two divisions-Product Revenue and Services & Other Revenue. The Product Revenue unit consists of consumables and instruments revenue, while the Services and Other Revenue unit consists of sequencing, genotyping, and instrument service contract revenue.

Key developments:

In 2020, Illumina's COVID response: Illumina partnered with ID by DNA Partner to deliver NGS Infectious Disease solutions. The partnership aims to accelerate Next-generation sequencing adoption of clinical infectious disease testing. This partnership also aims to make next-generation software with powerful bioinformatics software that can turn data into actionable insights.

Why Purchase the Report?

  • Visualize the composition of the global Cancer Tumor Profiling market segmentation by Cancer Type, by Technology type, by Biomarker type, by Application and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in Cancer Tumor Profiling market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of Cancer Tumor Profiling market- level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global Cancer Tumor Profiling market report would provide an access to an approx. market data 61 tables, 55 figures and 240 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Table of Contents

1. Global Cancer Tumor Profiling Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Cancer Tumor Profiling Market - Market Definition and Overview

3. Global Cancer Tumor Profiling Market - Executive Summary

  • 3.1. Market Snippet by Cancer Type
  • 3.2. Market Snippet by Technology Type
  • 3.3. Market Snippet by Biomarker Type
  • 3.4. Market Snippet by Application
  • 3.5. Market Snippet by Region

4. Global Cancer Tumor Profiling Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing incidence of cancer cases worldwide
    • 4.1.2. Restraints:
      • 4.1.2.1. Technical issues in sample collection and storage conditions
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Cancer Tumor Profiling Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Cancer Tumor Profiling Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Cancer Tumor Profiling Market - By Cancer Type

  • 7.1. Introduction
  • 7.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
  • 7.3. Market Attractiveness Index, By Cancer Type
      • 7.3.1.1. Lung Cancer*
      • 7.3.1.2. Introduction
      • 7.3.1.3. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 7.3.2. Prostate Cancer
    • 7.3.3. Breast Cancer
    • 7.3.4. Colorectal cancer
    • 7.3.5. Melanoma cancer
    • 7.3.6. Others

8. Global Cancer Tumor Profiling Market - By Technology Type

  • 8.1. Introduction
  • 8.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
  • 8.3. Market Attractiveness Index, By Technology type
    • 8.3.1. Immunoassays*
      • 8.3.1.1. Introduction
      • 8.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 8.3.2. Next-generation Sequencing,
    • 8.3.3. Polymerase chain reaction,
    • 8.3.4. In-Situ Hybridization,
    • 8.3.5. Microarray
    • 8.3.6. Others

9. Global Cancer Tumor Profiling Market - By Biomarker Type

  • 9.1. Introduction
  • 9.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Biomarker type
  • 9.3. Market Attractiveness Index, By Biomarker type
    • 9.3.1. Genomics biomarker*
      • 9.3.1.1. Introduction
      • 9.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 9.3.2. Protein biomarker
    • 9.3.3. Others

10. Global Cancer Tumor Profiling Market - By Application

  • 10.1. Introduction
  • 10.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
  • 10.3. Market Attractiveness Index, By Application
    • 10.3.1. Research applications*
      • 10.3.1.1. Introduction
      • 10.3.1.2. Market Size Analysis, and Y-o-Y Growth Analysis (%)
    • 10.3.2. Clinical applications
    • 10.3.3. Diagnostics
    • 10.3.4. Personalized medicines
    • 10.3.5. Others

11. Global Cancer Tumor Profiling Market - By Region

  • 11.1. Introduction
  • 11.2. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region
  • 11.3. Market Attractiveness Index, By Region
  • 11.4. North America
    • 11.4.1. Introduction
    • 11.4.2. Key Region-Specific Dynamics
    • 11.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.4.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.4.7.1. U.S.
      • 11.4.7.2. Canada
      • 11.4.7.3. Mexico
  • 11.5. Europe
    • 11.5.1. Introduction
    • 11.5.2. Key Region-Specific Dynamics
    • 11.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.5.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.5.7.1. Germany
      • 11.5.7.2. U.K.
      • 11.5.7.3. France
      • 11.5.7.4. Italy
      • 11.5.7.5. Spain
      • 11.5.7.6. Rest of Europe
  • 11.6. South America
    • 11.6.1. Introduction
    • 11.6.2. Key Region-Specific Dynamics
    • 11.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.6.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.6.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.6.7.1. Brazil
      • 11.6.7.2. Argentina
      • 11.6.7.3. Rest of South America
  • 11.7. Asia Pacific
    • 11.7.1. Introduction
    • 11.7.2. Key Region-Specific Dynamics
    • 11.7.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.7.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.7.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.7.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.7.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 11.7.7.1. China
      • 11.7.7.2. India
      • 11.7.7.3. Japan
      • 11.7.7.4. Australia
      • 11.7.7.5. Rest of Asia Pacific
  • 11.8. Middle East and Africa
    • 11.8.1. Introduction
    • 11.8.2. Key Region-Specific Dynamics
    • 11.8.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Cancer Type
    • 11.8.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Technology Type
    • 11.8.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Biomarker Type
    • 11.8.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Application
    • 11.8.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country

12. Global Cancer Tumor Profiling Market - Company Profiles

  • 12.1. Illumina Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. QIAGEN N.V,
  • 12.3. NeoGenomics Laboratories,
  • 12.4. Genomic Health Inc,
  • 12.5. Caris Life Sciences,
  • 12.6. Helomics Corporation,
  • 12.7. NanoString Technologies, Inc,
  • 12.8. Sysmex Corporation,
  • 12.9. Ribomed Biotechnologies, Inc,
  • 12.10. Roche Diagnostics.

LIST NOT EXHAUSTIVE

13. Global Cancer Tumor Profiling Market - Premium Insights

14. Global Cancer Tumor Profiling Market - DataM

  • 14.1. Appendix
  • 14.2. About Us and Services
  • 14.3. Contact Us